Third-quarter results show strength of US recovery
This article was originally published in Clinica
The latest third-quarter results from large US medtech companies illustrate the strength of recovery in the sector after the death of reform attempts. Most companies have reported profit growth rates of around 20% compared with the previous year on similar sales increases.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.